WO2002000183A2 - Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin - Google Patents
Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin Download PDFInfo
- Publication number
- WO2002000183A2 WO2002000183A2 PCT/US2001/041154 US0141154W WO0200183A2 WO 2002000183 A2 WO2002000183 A2 WO 2002000183A2 US 0141154 W US0141154 W US 0141154W WO 0200183 A2 WO0200183 A2 WO 0200183A2
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- egf
- skin
- composition
- tyrosine kinase
- radiation
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K8/00—Cosmetics or similar toiletry preparations
- A61K8/18—Cosmetics or similar toiletry preparations characterised by the composition
- A61K8/30—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds
- A61K8/49—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds
- A61K8/4973—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom
- A61K8/498—Cosmetics or similar toiletry preparations characterised by the composition containing organic compounds containing heterocyclic compounds with oxygen as the only hetero atom having 6-membered rings or their condensed derivatives, e.g. coumarin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/16—Emollients or protectives, e.g. against radiation
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61Q—SPECIFIC USE OF COSMETICS OR SIMILAR TOILETRY PREPARATIONS
- A61Q19/00—Preparations for care of the skin
- A61Q19/08—Anti-ageing preparations
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2800/00—Properties of cosmetic compositions or active ingredients thereof or formulation aids used therein and process related aspects
- A61K2800/74—Biological properties of particular ingredients
- A61K2800/78—Enzyme modulators, e.g. Enzyme agonists
- A61K2800/782—Enzyme inhibitors; Enzyme antagonists
Definitions
- This invention relates to new methods for using tyrosine kinase inhibitors, more specifically epidermal growth factor receptor (EGF-R) inhibitors, in the prevention and treatment of photoaging in human skin, especially photoaging from ultraviolet radiation, and most especially from the sun.
- tyrosine kinase inhibitors more specifically epidermal growth factor receptor (EGF-R) inhibitors
- EGF-R epidermal growth factor receptor
- UV irradiation of human skin not only induces enzymes (MMPs) that degrade collagen in the dermal matrix, it also inhibits the biosynthesis of collagen.
- MMPs enzymes
- UV irradiation not only causes degradation of the collagen structure, it also prevents its reconstruction.
- Protein tyrosine kinases are involved in regulating critical functions in mammalian cells (e.g., cell growth, cell death, inflammation, and so on). There are two classes of protein tyrosine kinases: receptor protein tyrosine kinases and non-receptor protein tyrosine kinases.
- protein tyrosine kinase inhibitors inhibit the activity of protein kinases such as tyrosine kinases and may act reversibly or irreversibly on the kinase to prevent its activation.
- the epidermal growth factor receptor family e.g., EGF-R or ErbB
- PDGF platelet-derived growth factor receptor family
- FGF-R fibroblast growth factor receptor family
- Patents 5,840,883; 5,935,993; 5,891 ,917; 5,773,459; 5,710,173; 5,686,457; 5,656,655; 5,650,415; 5,929,081 ; 5,760,041 ; 5,886,020; 5,880,141 ; 5,880,130; 5,869,485; 5,840,880; 5,834,504; 5,763,470; 5,374,652; 5,302,606; 5,108,921 ; 5,196,446; 5,914,343; and 5,911 ,995; the disclosures of which are incorporated herein by reference.
- Other protein tyrosine kinase inhibitors are described in the following abstracts: T.
- EGF-R inhibitors including AG-494 (a member of the tyrphostin family of tyrosine kinase inhibitors), AG-825 (5-[(Benzthiazol-2-yl)thiomethyl]-4-hydroxy-3-methoxybenzylidenecyano- acetamide), AG-1478 (4-(3-Chloroanilino)-6,7-dimethoxyquinazoline), EI-146 (an Erbstatin analog), Methyl 2,5-dihydroxycinnamate, HDBA (2-Hydroxy-5-(2,5-dihydroxybenzylamino)-2-hydroxybenzoic acid; Onoda et al., J.
- this invention provides a method for inhibiting photoaging of human skin by application to the skin, prior to UV exposure, of an inhibitor of EGF-R.
- Natural compounds such as genistein (a soy isoflavone), are preferred.
- this invention provides a composition for inhbiting photoaging of human skin, which comprises a combination of UVA and UVB blockers, as well as an EGF-R inhibitor, and preferably an additional MMP inhibitor such as a retinoid, a direct acting MMP inhibitor (such as Gaiardin), and/or a compound that inhibits the cytochrome P-450 mediated degradation of retinoids.
- Fig. 1 is a cartoon showing two pathways by which UV radiation from the sun may cause photoaging in human skin.
- Figs. 2-5 are the results of in vivo testing of human subjects' skin exposed to UV radiation and then biopsied, wherein their skin had been pretreated with a genistein solution to determine the effect on the expected increase in, respectively, JNK activation, cJUN protein, MMP-1 mRNA, and EGF-R phosphorylation after exposure of the skin to UV radiation. DESCRIPTION OF THE INVENTION
- compositions and methods for inhibiting MMP formation are believed to work by inhibiting the growth factor receptor pathways responsible for these detrimental effects in UV-irradiated human skin.
- EGF epidermal growth factor
- PTK protein tyrosine kinase
- EGF-R PTK inhibitors by blocking UV activation of EGF-R with the use of specific EGF-R PTK inhibitors, one can block UV induction of MMPs.
- administration of PTK inhibitors of EGF-R prevent UV-induced photoaging (by collagen degradation) in human skin.
- UV radiation from the sun activates both cytokine receptors and growth factor receptors.
- Each receptor though its own signalling pathway, results in the creation of activated protein-1 (AP-1), a heterodimer of cJUN and cFOS proteins.
- This invention principally concerns inhibiting the growth factor receptor pathway by which EGF-R functions, although it should be apparent from Fig. 1 that inhibiting both of the receptor pathways would be beneficial for inhibiting photoaging of human skin. In fact, our results indicate that all direct EGF-R inhibitors actually inhibit both of these pathways.
- the EGF-R molecule includes as part of its structure an activatable protein tyrosine kinase (PTK).
- PTK protein tyrosine kinase
- the receptor itself was tested for the EGF-R protein to assure it was, in fact, present (i.e., controls for the experiments which measured the total tyrosine kinase present, both phosphorylated and unphosphorylated).
- the results show a consistent and essentially constant amount of EGF-R protein, confirming that the receptor was present in all of the cell extracts.
- EGF, UV, IL-1 , and TNF were seen to activate EGF-R.
- the cells were also treated with PD 153035 and the respective challenging agents, the amount of phosphorylated tyrosine kinase from EGF-R was essentially the same as that seen in untreated cells. Accordingly, PD 153035 clearly inhibits phosphorylation (activation) of the tyrosine kinase function of EGF-R.
- MMPs may also be induced via IL-1 , but because its receptor does not include protein tyrosine kinase activity as EGF-R does, it could be activated by recruiting a kinase.
- IRAK IL-1 Receptor-Activated Kinase
- IL-1 R the IL-1 receptor
- EGF-treated cells were found to have a significant amount of IRAK acitivty in comparison with the baseline level.
- Cells treated with PD 153035 and then challenged with UV or EGF clearly had less phosphorylated IRAK than those without the PD 153035 pretreatment.
- PD 153035-treated cells exposed to IL-1 showed no reduction in phosphorylated IRAK.
- UV, IL-1 , and EGF each induces IRAK phosphorylation
- pretreatment with PD 153035 inhibits the IRAK phosphorylation due to challenge with UV or EGF, but not when challenged with IL-1.
- EGF-R protein tyrosine kinase inhibitor might have been expected to inhibit the EGF-R activation by UV irradiation, it would not have been expected to inhibit the IL-1 R activation by UV irradiation. While not desirous of being constrained to a particular theory of operation, it appears that there may be biochemical signalling (crosstalk) between the EGF-R pathway and the IL-1 R pathway, where activation of the EGF-R pathway results in activation of the IL-1 pathway. Accordingly, if this finding is accurate, one can further explain our invention as the use of an EGF-R tyrosine kinase inhibitor to inhibit UV-induced MMPs from both pathways.
- Such compounds include genistein (4',5,7- trihydroxyisoflavone), suramin sodium (and related derivatives), heribimycin-A, quercetin, lavendustin-A, erbstatin, benzylidenemalononitriles (referred to a tyrphostins, for tyrosine phosphorylation //ihibitors), brominated quinazolines (such as PD-160678 and PD-168383), phenylamino- and pyrazolopyrimidine and pyrrolopyrimidine compounds (such as STI-571and PKI-166), thioindoles, dianilinopthalimides, anthraquinones, and SU-5416 and SU-6668, and derivatives thereof.
- genistein 4',5,7- trihydroxyisoflavone
- suramin sodium and related derivatives
- heribimycin-A quercetin
- lavendustin-A lavendustin-A
- the test solution was placed (or on adjacent areas if both solutions were used), and the areas occluded for 24 hours; thereafter, the area was biopsied, or it was exposed to 2 MEDs of UV radiation and biopsied after exposure.
- the UV source was a bank of UVB fluorescent lamps model F36T12 (putting out 26% in visible and near IR wavelengths), filtered with Kodacel TA401/407 filter (available from Kodak, Rochester, NY). Total irradiation 290-800 nm 17 inches from the source was 1.49 x 10-3 w/cm 2 .
- Fig. 2 depicts the results from the skin of volunteers tested for the change in JNK activation.
- UV radiation and ROS activate the cytokine receptor pathway, which, through JNK, creates AP-1 , leading to premature aging due to the sun.
- the results shown in Fig. 2 indicate that UV radiation significantly increased the activation of JNK, but that 5% genistein significantly reduced the amount of JNK activated.
- topical genistein is an effective composition for inhibiting photoaging through the cytokine pathway.
- Fig. 3 depicts the results from the skin of volunteers tested for any changes in the amount of cJUN protein induced by UV radiation. The same procedure as described above was repeated, except that biopsy for cJUN protein was taken 8 hours after exposure to the UV radiation. As shown in the figure, topically applied genistein solution significantly inhibited the increased in the amount of cJUN protein in the skin after UV exposure, as compared with vehicle-treated skin. The inset in the figure is a Western blot showing the amount of cJUN protein in genistein-treated versus vehicle-treated skin.
- Fig. 4 depicts the results from the skin of volunteers tested for the change in the amount of MMP-1 mRNA induced by UV radiation.
- Fig. 5 depicts the results from the skin of volunteers tested for the amount of EGF-R phosphorylated after exposure to UV radiation. As described above, EGF-R is activated when phosphorylated. Reducing, if not preventing, phosphorylation of EGF-R would decrease its activity and the concomitant increase in MMPs after exposure to UV radiation. First, after the 24 hour occlusion, the volunteers' skin was biopsied tested to determine whether the vehicle alone or the genistein solution alone induced phosphorylation in EGF-R.
- Fig. 5 The two left hand bars of the histogram in Fig. 5 indicate that the genistein solution did not induce EGF-R phosphorylation.
- the volunteers' skin was exposed to 2 MEDs of UV radiation, and thirty minutes (30 min.) after exposure their skin was again biopsied and tested.
- genistein treated skin showed significantly less of the phosphorylation of EGF-R found in vehicle-treated skin. Accordingly, topically applied genistein inhibits the growth factor receptor pathway that leads to photoaged skin after exposure of the skin to UV radiation.
- EGF-R PTK inhibitors are believed to function much earlier in the pathways that lead to upregulation of MMPs and inhibition of collagen biosynthesis, there may also be some advantage to using these compounds in combination with retinoids and other MMP inhibitors, including direct acting MMP inhibitors, P-450 inhibitors (which inhibit the enzyme that degrades retinoic acid receptors in the skin), "antioxidants” (also appear to inhibit MMP upregulation), sunscreens, and the like; especially in that lower doses of compounds may likely be as efficacious when used in these types of combinations.
- Genistein, and its ⁇ -glucoside conjugate genistin can be found in soy milk, tofu (bean curd), miso (bean paste), natto (fermented soybeans), and soy sauce.
- Other natural EGFR activation inhibitors, and derivatives thereof, include staurosporine, aeroplysinin (K. Schuding et al., "Synthesis and biological evaluation of aeroplysinin analogues: a new class of receptor tyrosine kinase inhibitors," Bioorg Med Chem 1998 Aug; 6(8):1153-62; H.
- One screening method for determining the ability of a given compound to inhibit the activation of EGFR is to use cultured cells or an organ culture, preferably using human cells (such as the human skin organ culture described by S.W. Stoll and J.T. Elder, "Retinoid regulation of heparin-binding EGF-like growth factor gene expression in human keratinocytes and skin", Exp. Dermatol., 1998: 7: 391-397) that have been challenged with an agonist known to induce EGFR activation, such as EGF.
- human cells such as the human skin organ culture described by S.W. Stoll and J.T. Elder, "Retinoid regulation of heparin-binding EGF-like growth factor gene expression in human keratinocytes and skin", Exp. Dermatol., 1998: 7: 391-397
- the test agonist compound can also be used in combination with a Western blot to assure that the total amount of EGFR is unchanged and that only the amount of EGFR activated/phosphorylated is increased (as was the case with the experiments shown in Fig. 5).
- the cultured cells or organ culture are exposed to the desired agonist compound, then the test inhibitor compound is added, and finally the cells are examined (such via Western blot) to determine the extent of EGFR activation.
- the amount of inhibitor used therapeutically depends on the selectivity of the inhibitor for the EGFR, whether it is a reversible or irreversible inhibitor, its ability to penetrate the skin (the composition may include a penetration enhancer), its stability, its metabolism, and the like. In general, 0.1 % to 10%, more preferably about 5% by weight of the composition of a reversible inhibitor is used; lesser amounts of an irreversible inhibitor are used. A combination of reversible and irreversible inhibitors can also be used.
- Retinoids include natural and synthetic analogs of vitamin A (retinol), vitamin A aldehyde (retinal), vitamin A acid (retinoic acid (RA)), including a ⁇ -trans, 9-cis, and 13-c/s retinoic acid), etretinate, and others as described in EP-A2-0 379367, US 4,887,805, and US 4,888,342 (the disclosures of which are all incorporated herein by reference).
- Various synthetic retinoids and compounds having retinoid activity are expected to be useful in this invention, to the extent that they exhibit retinoid activity in vivo, and such are described in various patents assigned on their face to Allergan Inc., such as in the following U.S. Patents, numbered: 5,514,825; 5,698,700;
- MMPs are also inhibited by BB2284 (described by Gearing, A.J.H. et al., Nature (1994) 370:555-557), GI129471 (described by McGeehan
- TIMPs tissue inhibitors of metalloproteinases, which inhibit vertebrate collagenases and other metalloproteases, including gelatinase and stromelysin.
- Still other compounds useful for the present invention include direct inhibitors of
- MMPs such as hydroxamate and hydroxy-urea derivatives, including those such as Gaiardin, Batimastat, and Marimastat, and those disclosed in EP-A1-0 558635 and EP-A1-0 558648 (as useful for inhibiting MMPs in the treatment of, among other etiologies, skin ulcers, skin cancer, and epidermolysis bullosa).
- Retinoids have been reported by Goldsmith, L.A.
- retinoids are converted into retinoic acide (RA) as the active form.
- Retinoic acid (RA) is then metabolized to inactivation by hydroxylation (via RA 4-hydroxylase) to 4-hydroxy-RA, which is then oxidized to 4-oxo-RA by a reaction mediated by a cytochrome P-450-dependent monooxygenase system.
- Examples of compounds dermatologically acceptable and having or likely to have inhibitory effects on the P-450-mediated degradation of RA include azoles, especially triazoles, including, for example, ketoconazole (US 4,144,346 and 4,223,036), fluconazole (US 4,404,216), itraconazole (US 4,267,179), liarozole, irtemazole, and the like; compounds related to these that may also be useful include, for example, diazines such as flucytosine. It would also be beneficial to use such cytochrome P-450 inhibitors in combination with a reduced amount of retinoid; the P-450 inhibitor decreases the metabolic elimination of the retinoid and so less retinoid is needed to achieve the same result.
- MMP inhibitors include the tetracyclines and derivatives thereof, such as minocycline, roliteracycline, chlortetracycline, methacycline, oxytetracycline, doxycycline, demeclocycline, and the various salts thereof. Because of possible allergic or sensitization reactions, the topical adminstration of tetracyclines should be monitored carefully for such untoward reactions.
- MMP inhibitors also include genistein and quercetin (as described in
- NAC N-acetyl cystein
- GMP MMP inhibitors to the extent that they might function by quenching or otherwise reducing free radicals and reactive oxygen species which initiate or lead to MMP induction, such as via the MAP kinase cascade.
- Antioxidants include glutathione and its precursors, such as N-acetyl cysteine (NAC) (as mentioned above), more broadly N-CH 3 (CH 2 ) n CO cysteine (wherein n is an integer from zero to eight, more preferably not more than 4), and related compounds and derivates thereof as described in U.S. Pat. No. 5,296,500 (the disclosure of which is incorporated herein by reference).
- NAC N-acetyl cysteine
- N-CH 3 (CH 2 ) n CO cysteine wherein n is an integer from zero to eight, more preferably not more than 4
- Antioxidants also include: (i) lipid-soluble compounds such as ⁇ -carotene and its derivatives, other carotenoids, and vitamin E and related tocopherols; (ii) water-soluble compounds such as vitamin C, glutathione, and NAC; and (iii) other compounds (such as one of the pigments that makes tomatoes red, and lipoic acid found in potatoes).
- lipid-soluble compounds such as ⁇ -carotene and its derivatives, other carotenoids, and vitamin E and related tocopherols
- water-soluble compounds such as vitamin C, glutathione, and NAC
- other compounds such as one of the pigments that makes tomatoes red, and lipoic acid found in potatoes.
- UV blockers are known in the paint and dye industry to prevent pigment or color degradation of cars, homes, and clothing.
- a particularly preferred UVA 1/2 -blocker for use on human skin is PARSOL ® 1789 and PARSOL ® MCX (Schering-Plough), as well as those mentioned in
- UV blockers inhibit induction of cJUN mRNA and of collagenase and gelatinase. Most preferably, UV blockers should block radiation of both less than about 320 nm and between about 380 and 390 nm.
- Other sunscreen compositions are described in our co-pending application 60/216244, filed 6 July 2000, and the above-mentioned U.S. Pat. No. 6,130,254, the disclosures of which are incorporated herein by reference.
- Various changes, modification, and additions may become apparent to one of ordinary skill in these arts, and such within the spirit of this invention are intended to be included with the scope of the claims appended hereto.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Dermatology (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Organic Chemistry (AREA)
- Gerontology & Geriatric Medicine (AREA)
- Birds (AREA)
- Toxicology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Cosmetics (AREA)
Abstract
Description
Claims
Priority Applications (6)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU2001272028A AU2001272028A1 (en) | 2000-06-26 | 2001-06-26 | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
MXPA03000089A MXPA03000089A (en) | 2000-06-26 | 2001-06-26 | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin. |
CA002414406A CA2414406A1 (en) | 2000-06-26 | 2001-06-26 | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
JP2002504965A JP2004504276A (en) | 2000-06-26 | 2001-06-26 | Use of an EGF-R protein tyrosine kinase inhibitor to prevent photoaging of human skin |
EP01951098A EP1294349A2 (en) | 2000-06-26 | 2001-06-26 | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
BR0112355-6A BR0112355A (en) | 2000-06-26 | 2001-06-26 | Use of egf-r tyrosine kinase protein inhibitors for the prevention of human skin photoaging |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US21394000P | 2000-06-26 | 2000-06-26 | |
US60/213,940 | 2000-06-26 |
Publications (2)
Publication Number | Publication Date |
---|---|
WO2002000183A2 true WO2002000183A2 (en) | 2002-01-03 |
WO2002000183A3 WO2002000183A3 (en) | 2002-07-25 |
Family
ID=22797119
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2001/041154 WO2002000183A2 (en) | 2000-06-26 | 2001-06-26 | Use of egf-r protein tyrosine kinase inhibitors for preventing photoaging in human skin |
Country Status (8)
Country | Link |
---|---|
US (2) | US20020012641A1 (en) |
EP (1) | EP1294349A2 (en) |
JP (1) | JP2004504276A (en) |
AU (1) | AU2001272028A1 (en) |
BR (1) | BR0112355A (en) |
CA (1) | CA2414406A1 (en) |
MX (1) | MXPA03000089A (en) |
WO (1) | WO2002000183A2 (en) |
Cited By (3)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1230919A2 (en) * | 2001-02-12 | 2002-08-14 | Warner-Lambert Company | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage |
EP2295028A1 (en) * | 2008-03-31 | 2011-03-16 | Shiseido Company, Ltd. | Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method |
US10959981B2 (en) | 2013-05-06 | 2021-03-30 | Amorepacific Corporation | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2494061C (en) * | 2002-07-31 | 2011-06-14 | Wayne R. Danter | Protein tyrosine kinase inhibitors |
US7629347B2 (en) * | 2002-10-09 | 2009-12-08 | Critical Outcome Technologies, Inc. | Protein tyrosine kinase inhibitors |
JP2005263645A (en) * | 2004-03-16 | 2005-09-29 | Shiseido Co Ltd | Method for inhibiting inflammation and composition for the same |
US20080119530A1 (en) * | 2006-09-29 | 2008-05-22 | Hansen Laura A | Method for treatment and prevention of ultraviolet light induced skin pathologies |
JP5746807B2 (en) * | 2006-12-28 | 2015-07-08 | アルロン・ジャパン株式会社 | Cosmetic composition for skin |
WO2008083491A1 (en) | 2007-01-11 | 2008-07-17 | Critical Outcome Technologies Inc. | Compounds and method for treatment of cancer |
US20080269339A1 (en) * | 2007-04-26 | 2008-10-30 | Thomas Robert Sutter | Combined use of egf pathway inhibitors and differentiation promoting compounds |
US20120065272A1 (en) * | 2007-10-17 | 2012-03-15 | Newtree Co., Ltd. | Novel use of panduratin derivatives or extract of kaempferia pandurata comprising the same |
JP6309184B2 (en) * | 2007-11-15 | 2018-04-11 | ザ ジェネラル ホスピタル コーポレイション | Methods and compositions for reduction of skin damage |
EP2225226B1 (en) * | 2007-12-26 | 2016-08-17 | Critical Outcome Technologies, Inc. | Compounds and their use in a method for treatment of cancer |
WO2009122540A1 (en) * | 2008-03-31 | 2009-10-08 | 株式会社資生堂 | Wrinkle-preventing or improving agent for oral, injection or external skin application and cosmetic method |
WO2010006438A1 (en) | 2008-07-17 | 2010-01-21 | Critical Outcome Technologies Inc. | Thiosemicarbazone inhibitor compounds and cancer treatment methods |
WO2011120153A1 (en) | 2010-04-01 | 2011-10-06 | Critical Outcome Technologies Inc. | Compounds and method for treatment of hiv |
Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997046208A2 (en) * | 1996-06-07 | 1997-12-11 | Mt. Sinai School Of Medicine Of The City Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
WO1998010767A2 (en) * | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
WO1998055075A2 (en) * | 1997-06-04 | 1998-12-10 | Regents Of The University Of Michigan | Compositions and methods for inhibiting photoaging of skin |
WO1998056373A1 (en) * | 1997-06-11 | 1998-12-17 | Gorbach Sherwood L | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
WO1999051220A1 (en) * | 1998-04-02 | 1999-10-14 | The Regents Of The University Of Michigan | Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5837224A (en) * | 1996-01-19 | 1998-11-17 | The Regents Of The University Of Michigan | Method of inhibiting photoaging of skin |
CN100360121C (en) * | 1997-02-25 | 2008-01-09 | 密执安州立大学董事会 | Methods and compositions for preventing and treating chronological aging in human skin |
DE19713092A1 (en) * | 1997-03-27 | 1998-10-01 | Wacker Chemie Gmbh | Complexes of gamma-cyclodextrin and retinol or retinol derivatives, as well as processes for their preparation and their use |
AUPP112497A0 (en) * | 1997-12-24 | 1998-01-22 | Novogen Research Pty Ltd | Compositions and method for protecting skin from UV induced immunosupression and skin damage |
FR2782919B1 (en) * | 1998-09-04 | 2001-05-25 | Roc Sa | COMPOSITION AGAINST AGING AND ITS USE |
US6258820B1 (en) * | 1999-03-19 | 2001-07-10 | Parker Hughes Institute | Synthesis and anti-tumor activity of 6,7-dialkoxy-4-phenylamino-quinazolines |
JP2001039849A (en) * | 1999-07-27 | 2001-02-13 | Shiseido Co Ltd | Agent for promoting production of collagen |
-
2001
- 2001-06-26 AU AU2001272028A patent/AU2001272028A1/en not_active Abandoned
- 2001-06-26 JP JP2002504965A patent/JP2004504276A/en active Pending
- 2001-06-26 WO PCT/US2001/041154 patent/WO2002000183A2/en not_active Application Discontinuation
- 2001-06-26 EP EP01951098A patent/EP1294349A2/en not_active Withdrawn
- 2001-06-26 BR BR0112355-6A patent/BR0112355A/en not_active IP Right Cessation
- 2001-06-26 MX MXPA03000089A patent/MXPA03000089A/en unknown
- 2001-06-26 CA CA002414406A patent/CA2414406A1/en not_active Abandoned
- 2001-06-26 US US09/891,881 patent/US20020012641A1/en not_active Abandoned
-
2005
- 2005-08-22 US US11/208,947 patent/US20050281764A1/en not_active Abandoned
Patent Citations (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO1997046208A2 (en) * | 1996-06-07 | 1997-12-11 | Mt. Sinai School Of Medicine Of The City Of New York | Genistein as a preventive against ultraviolet induced skin photodamage and cancer |
WO1998010767A2 (en) * | 1996-09-13 | 1998-03-19 | Sugen, Inc. | Use of quinazoline derivatives for the manufacture of a medicament in the treatment of hyperproliferative skin disorders |
WO1998055075A2 (en) * | 1997-06-04 | 1998-12-10 | Regents Of The University Of Michigan | Compositions and methods for inhibiting photoaging of skin |
WO1998056373A1 (en) * | 1997-06-11 | 1998-12-17 | Gorbach Sherwood L | Isoflavonoids for treatment and prevention of aging skin and wrinkles |
WO1999051220A1 (en) * | 1998-04-02 | 1999-10-14 | The Regents Of The University Of Michigan | Methods and compositions for reducing uv-induced inhibition of collagen synthesis in human skin |
Cited By (5)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1230919A2 (en) * | 2001-02-12 | 2002-08-14 | Warner-Lambert Company | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage |
EP1230919A3 (en) * | 2001-02-12 | 2002-12-18 | Warner-Lambert Company | Use of a composition comprising a retinoid and an erb inhibitor in the preparation of a medicament for the treatment of retinoid skin damage |
EP2295028A1 (en) * | 2008-03-31 | 2011-03-16 | Shiseido Company, Ltd. | Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method |
EP2295028A4 (en) * | 2008-03-31 | 2013-11-13 | Shiseido Co Ltd | Preparation for preventing or ameliorating wrinkles, to be taken orally, through injection, or through external application to skin, and cosmetic method |
US10959981B2 (en) | 2013-05-06 | 2021-03-30 | Amorepacific Corporation | Composition for preventing or treating climacteric symptoms comprising soybean extract comprising coumestrol as an active ingredient |
Also Published As
Publication number | Publication date |
---|---|
WO2002000183A3 (en) | 2002-07-25 |
BR0112355A (en) | 2005-04-19 |
EP1294349A2 (en) | 2003-03-26 |
JP2004504276A (en) | 2004-02-12 |
AU2001272028A1 (en) | 2002-01-08 |
US20020012641A1 (en) | 2002-01-31 |
CA2414406A1 (en) | 2002-01-03 |
US20050281764A1 (en) | 2005-12-22 |
MXPA03000089A (en) | 2004-09-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US20050281764A1 (en) | Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin | |
Lephart | Skin aging and oxidative stress: Equol’s anti-aging effects via biochemical and molecular mechanisms | |
CA2281944C (en) | Methods and compositions for preventing and treating chronological aging in human skin | |
US5837224A (en) | Method of inhibiting photoaging of skin | |
Pandel et al. | Skin photoaging and the role of antioxidants in its prevention | |
Parvez et al. | Survey and mechanism of skin depigmenting and lightening agents | |
US6942870B2 (en) | Compositions and methods using direct MMP inhibitors for inhibiting photoaging of skin | |
KR101089071B1 (en) | Use of ellagic acid for the treatment of canities | |
KR100930257B1 (en) | 3H-1,2-dithiol-3-thione, anetol dithiolethion, sulfolaphan, phenethyl isothiocyanate, 6- (methylsulfinyl) hexyl isothiocyanate and allyl isoiso Use of Thiocyanate | |
JP2003513895A (en) | Soy-containing composition for bleaching and skin care | |
JP2004512295A (en) | Use of a combination of at least one carotenoid and at least one isoflavonoid for treating the signs of skin aging | |
KR100953848B1 (en) | Use of coumarin, butylated hydroxyanisole and ethoxyquine for the treatment of canities | |
AU2006246530A1 (en) | Use of EGF-R protein tyrosine kinase inhibitors for preventing photoaging in human skin | |
Welsh et al. | Topical all-trans retinoic acid augments ultraviolet radiation-induced increases in activated melanocyte numbers in mice | |
Padmavathi et al. | Efficacy of Topical Soy Isoflavonoid Extract in Prevention and Reversal of Photo-Ageing in Guinea Pig Model | |
AU701132C (en) | Method of inhibiting photoaging of skin | |
KR100352687B1 (en) | Cosmetics to prevent photoaging | |
Godic | SKIN PHOTOAGING AND THE ROLE OF ANTIOXIDANTS IN ITS PREVENTION | |
AU2002301116B2 (en) | Compositions and Methods for Inhibiting Photoaging of Skin | |
Tanaka et al. | Current status of whitening agents and their future in Japan | |
MXPA99007883A (en) | Methods and compositions for preventing and treating chronological aging in human skin |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A2 Designated state(s): AE AG AL AU BA BB BG BR BZ CA CN CR CU CZ DM DZ EE GD GE HR HU ID IL IN IS JP KP KR LC LK LR LT LV MA MD MG MK MN MX NO NZ PL PT RO SG SI SK TR TT UA UZ VN YU ZA |
|
AL | Designated countries for regional patents |
Kind code of ref document: A2 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE TR BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2414406 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2002 504965 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: PA/a/2003/000089 Country of ref document: MX |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001951098 Country of ref document: EP |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2001272028 Country of ref document: AU |
|
WWP | Wipo information: published in national office |
Ref document number: 2001951098 Country of ref document: EP |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWW | Wipo information: withdrawn in national office |
Ref document number: 2001951098 Country of ref document: EP |